A Semi-Mechanistic Population Pharmacokinetic Model of Noscapine in Healthy Subjects Considering Hepatic First-Pass Extraction and CYP2C9 Genotypes-Reference-Cited by-同舟云学术

A Semi-Mechanistic Population Pharmacokinetic Model of Noscapine in Healthy Subjects Considering Hepatic First-Pass Extraction and CYP2C9 Genotypes

Published:2024-05-29 Issue:2 Volume:24 Page:187-199
ISSN:1174-5886
Container-title:Drugs in R&D
language:en
Short-container-title:Drugs R D

Author:

Chen Zhendong^ORCID,Taubert Max,Chen Chunli,Boland Jana,Dong Qian,Bilal Muhammad,Dokos Charalambos,Wachall Bertil,Wargenau Manfred,Scheidel Bernhard,Wiesen Martin H. J.,Schaeffeler Elke,Tremmel Roman,Schwab Matthias,Fuhr Uwe

Funder

2022 ESI International High Impact Research Article Cooperation Program

China Scholarship Council

National Natural Science Foundation of Heilongjiang Province

International Postdoctoral Exchange Fellowship Program from the Office of China Postdoctoral Council

Robert Bosch Stiftung

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40268-024-00466-6.pdf

Reference49 articles.

1. Empey DW, Laitinen LA, Young GA, Bye CE, Hughes DT. Comparison of the antitussive effects of codeine phosphate 20 mg, dextromethorphan 30 mg and noscapine 30 mg using citric acid-induced cough in normal subjects. Eur J Clin Pharmacol. 1979;16(6):393–7.

2. Kamei J. Role of opioidergic and serotonergic mechanisms in cough and antitussives. Pulm Pharmacol. 1996;9(5–6):349–56.

3. Mooraki A, Jenabi A, Jabbari M, Zolfaghari MI, Javanmardi SZ, Mahmoudian M, et al. Noscapine suppresses angiotensin converting enzyme inhibitors-induced cough. Nephrology (Carlton). 2005;10(4):348–50.

4. Karlsson MO, Dahlström B, Neil A. Characterization of high-affinity binding sites for the antitussive [3H]noscapine in guinea pig brain tissue. Eur J Pharmacol. 1988;145(2):195–203.

5. Rahmanian-Devin P, Baradaran Rahimi V, Jaafari MR, Golmohammadzadeh S, Sanei-Far Z, Askari VR. Noscapine, an emerging medication for different diseases: a mechanistic review. Evid Based Complement Altern Med. 2021;2021:8402517.